Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ...

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of ...

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what ...

The program allows patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights ...

In addition to Prevent Blindness’s usual free resources, the organization is providing a dedicated webpage, fact sheets, and ...

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop ...

Patients express mixed feelings about AI in health care, favoring its use for documentation and administrative tasks while ...

Nicox completed the Denali Phase 3 trial for NCX 470, targeting open-angle glaucoma and ocular hypertension. NCX 470 combines ...

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for ...

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

PYC Therapeutics advances VP-001 for retinitis pigmentosa, gaining FDA insights for its upcoming registrational trial.